Which comes first in West Africa? Pharmaceutical regulatory convergence or regional market access.

Many an article has been written about the chicken and the egg! Which really did come first? In West Africa the pharmaceutical market is fragmented with multiple issues not just pertaining to quality of medication but also market access, regulation, financing, currency, contracts and human resource requirements, amongst several issues that have been highlighted by the various ECOWAS and AU reports on the pharmaceutical industry.

A few weeks ago, in Abuja the USTDA convened a fantastic workshop on the convergence of pharmaceutical regulations. For those of you not aware, the pharmaceutical industry is one of the most heavily regulated industries in the world due to the attendant risks that medications can carry for people. The USTDA together with the Corporate Council on Africa brought together national regulators, manufacturers, NGOs and other stakeholders to deliberate on regulatory convergence in West Africa.

For some of us it was extremely welcome to hear from the Nigerian, Ghanian, Ivorian and Senegalese national medicines regulatory authorities about the steps that had been taken to ensure convergence, it was clear that a lot had been done, however there is still a lot to do.

The elephant in the room was clear and present and some people touched on it. Regulatory convergence without a single West African market was half the battle won. Some would argue that without a working framework for a single market across West Africa regulatory convergence would be stillborn. The ability for West African manufacturers to be able to sell their produced in West Africa products across West Africa with reduced or removed trade barriers would dramatically improve the access to quality medicines for West Africans. This single change would improve the economics of doing business in West Africa and help local manufacturing to flourish. The ECOWAS customs union and external common tariff is a start and a push in the right direction and needs to be supported by the member states to allow a boost in intra West African trade.

At Quintex Pharma we are thrilled to be part of these discussions and excited by the approach the various national regulatory authorities have taken to harmonise regulatory requirements. We look forward to a future where trade across West Africa and indeed the whole of Africa is seamless.

Quintex Pharma Signs Technical Transfer Agreement with Fabtech Technologies Ltd for Pharmaceutical Manufacturing Intellectual Property

FOR IMMEDIATE RELEASE Quintex Pharma Signs Technical Transfer Agreement with Fabtech Technologies Ltd for Pharmaceutical Manufacturing Intellectual Property Delaware 27th November 2023 — Quintex Pharma, a Delaware based start-up pharmaceutical manufacturing company with its planned production base to be situated in Ghana, is thrilled to announce the signing of a ground breaking Technical Transfer Agreement with Fabtech Technologies Ltd, a renowned global innovator in pharmaceutical manufacturing solutions. This strategic collaboration marks a significant milestone in Quintex Pharma's mission to enhance healthcare access and quality across West Africa. The Technical Transfer Agreement encompasses the transfer of valuable pharmaceutical manufacturing intellectual property from Fabtech Technologies Ltd to Quintex Pharma, facilitating the expansion of Quintex Pharma's product portfolio and manufacturing capabilities. Fabtech Technologies Ltd, with its extensive experience and expertise in pharmaceutical manufacturing processes and technologies, will be instrumental in aiding Quintex Pharma's efforts to bolster its production capacities and optimize its manufacturing processes. This transfer of knowledge and technology is expected to strengthen Quintex Pharma's position as a leading provider of high-quality generic medications and contract manufacturing services in the region. Quintex Pharma is excited about the partnership: "This collaboration with Fabtech Technologies Ltd represents a significant step forward in our journey to provide affordable and effective pharmaceutical products in West Africa. We are confident that the transfer of intellectual property and technical expertise will enable us to develop and manufacture high-quality pharmaceuticals that meet the evolving healthcare needs of our region." Fozi Al Kailani, the representative of Fabtech Technologies Ltd, shared his enthusiasm for the collaboration: "We are pleased to partner with Quintex Pharma, a company that shares our commitment to innovation, quality, and improving healthcare access. This Technical Transfer Agreement aligns with Fabtech's mission to empower pharmaceutical manufacturers worldwide with cutting-edge technology and know-how." As Quintex Pharma and Fabtech Technologies Ltd embark on this mutually beneficial partnership, they anticipate that it will lead to innovations in pharmaceutical manufacturing, higher product quality, and increased availability of essential medications in West Africa. Both companies are committed to upholding the highest standards of quality and regulatory compliance throughout this collaboration. For media inquiries or more information about Quintex Pharma's Technical Transfer Agreement with Fabtech Technologies Ltd, please contact: Quintex Pharma corporate affairs team: [email protected] About Quintex Pharma: Quintex Pharma is a Delaware holdCo with pharmaceutical manufacturing based in Akuse, Ghana. Quintex Pharma is dedicated to providing high-quality generic medications and contract manufacturing services to improve healthcare access and quality in West Africa. About Fabtech Technologies Ltd: Fabtech Technologies Ltd is a global leader in pharmaceutical manufacturing solutions, specializing in cutting-edge technology and expertise for pharmaceutical manufacturers worldwide.